CervoMed to Participate in Upcoming Investor Conferences

CRVO 11.07.2024

Full Press ReleaseSEC FilingsOur CRVO Tweets

About Gravity Analytica

Recent News

  • 12.12.2024 - CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 12.10.2024 - CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
  • 11.27.2024 - CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Recent Filings

  • 01.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 12.10.2024 - 8-K Current report
  • 12.10.2024 - EX-99.1 EX-99.1

BOSTON,Nov. 07, 2024(GLOBE NEWSWIRE) --CervoMed Inc.(NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company’s Management will participate in the following investor conferences during the month of November:

Sidoti Virtual Micro Cap ConferenceFormat: Corporate presentationDate:Thursday, November 14, 2024Time:2:30 PM ETWebcast Link: clickhere

Stifel 2024 Healthcare ConferenceFormat: Corporate presentationDate:Tuesday, November 19, 2024Time:3:00 PM ETWebcast Link: clickhere

The webcast of the presentations will be accessible in the Investor section of the CervoMed websitehttps://www.cervomed.com/.

About CervoMedCervoMed Inc.(the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with early-stage DLB.

Investor Contact:PJ KelleherLifeSci AdvisorsInvestors@cervomed.com617-430-7579

Primary Logo

Source: CervoMed Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com